These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 23186654)

  • 1. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
    Asselah T
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):455-62. PubMed ID: 23199504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia management in patients with chronic viral hepatitis C.
    Hynicka LM; Heil EL
    Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
    Beste LA; Green PK; Ioannou GN
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Jul; 84(7):1097-105. PubMed ID: 22585728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
    Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
    Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM; Tanwar S; Dusheiko GM
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
    Marks KM; Jacobson IM
    Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.